JP2004509851A - 神経疾患治療用医薬組成物 - Google Patents

神経疾患治療用医薬組成物 Download PDF

Info

Publication number
JP2004509851A
JP2004509851A JP2002511731A JP2002511731A JP2004509851A JP 2004509851 A JP2004509851 A JP 2004509851A JP 2002511731 A JP2002511731 A JP 2002511731A JP 2002511731 A JP2002511731 A JP 2002511731A JP 2004509851 A JP2004509851 A JP 2004509851A
Authority
JP
Japan
Prior art keywords
substituted
compound
tartaric acid
hydrogen
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002511731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004509851A5 (cg-RX-API-DMAC7.html
Inventor
ダル，ゲリー・モーリス
ルコント，ジヤン−ピエール
カビール，フマーユーン
Original Assignee
ターガセプト，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ターガセプト，インコーポレイテッド filed Critical ターガセプト，インコーポレイテッド
Publication of JP2004509851A publication Critical patent/JP2004509851A/ja
Publication of JP2004509851A5 publication Critical patent/JP2004509851A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2002511731A 2000-07-14 2001-07-11 神経疾患治療用医薬組成物 Pending JP2004509851A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/616,743 US6432954B1 (en) 2000-07-14 2000-07-14 Pharmaceutical compositions and methods for use
PCT/US2001/021872 WO2002005798A2 (en) 2000-07-14 2001-07-11 Pharmaceutical compositions for treating neurological disorders

Publications (2)

Publication Number Publication Date
JP2004509851A true JP2004509851A (ja) 2004-04-02
JP2004509851A5 JP2004509851A5 (cg-RX-API-DMAC7.html) 2008-08-28

Family

ID=24470778

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002511731A Pending JP2004509851A (ja) 2000-07-14 2001-07-11 神経疾患治療用医薬組成物

Country Status (16)

Country Link
US (1) US6432954B1 (cg-RX-API-DMAC7.html)
EP (1) EP1311265B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004509851A (cg-RX-API-DMAC7.html)
CN (2) CN1680326A (cg-RX-API-DMAC7.html)
AT (1) ATE285773T1 (cg-RX-API-DMAC7.html)
AU (2) AU2290902A (cg-RX-API-DMAC7.html)
BR (1) BR0112130A (cg-RX-API-DMAC7.html)
CA (1) CA2415901A1 (cg-RX-API-DMAC7.html)
DE (1) DE60108130T2 (cg-RX-API-DMAC7.html)
HU (1) HUP0301553A3 (cg-RX-API-DMAC7.html)
IL (3) IL153577A0 (cg-RX-API-DMAC7.html)
NO (1) NO20030155L (cg-RX-API-DMAC7.html)
NZ (1) NZ523606A (cg-RX-API-DMAC7.html)
PL (1) PL360532A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002005798A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200300135B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511482A (ja) * 2002-10-02 2006-04-06 ターガセプト，インコーポレイテッド コリン作動性受容体を活性化できる化合物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070219238A1 (en) * 2004-04-21 2007-09-20 Basf Aktiengesellschaft Fungicidal Mixtures
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
EP2133337A1 (en) * 2006-05-09 2009-12-16 AstraZeneca AB Salt forms of (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-penten-2-amine
WO2008034041A2 (en) * 2006-09-15 2008-03-20 Astrazeneca Ab Therapeutic combinations
EP2112923A1 (en) 2007-01-22 2009-11-04 Targacept Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
CA2695214A1 (en) * 2007-07-31 2009-02-05 Targacept, Inc. Transdermal administration of (2s)-(4e)-n-methyl-5-(3-(5-is0pr0p0xypyridin)yl)-4-penten-2-amine
AU2011256866B2 (en) 2010-05-20 2014-05-22 Astrazeneca Ab New process for the preparation of aryl substituted olefinic amines

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996008468A1 (en) * 1994-09-14 1996-03-21 H. Lundbeck A/S Carbamoyloxy amine compounds
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
WO1999052525A1 (es) * 1998-04-15 1999-10-21 Laboratorios Del Dr. Esteve, S.A. Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos
WO1999065876A1 (en) * 1998-06-16 1999-12-23 R.J. Reynolds Tobacco Company Aryl substituted olefinic amines and their use as cholinergic receptors agonists
JP2000044533A (ja) * 1998-03-26 2000-02-15 Santen Pharmaceut Co Ltd 新規ウレア誘導体
JP2004503589A (ja) * 2000-07-14 2004-02-05 ターガセプト，インコーポレイテッド Ｅ−メタニコチンのジアシル酒石酸塩を含有する組成物
JP2005255694A (ja) * 2000-07-04 2005-09-22 Lts Lohmann Therapie-Systeme Ag 口腔または体腔内で有効成分を放出するための迅速分解性投与可能剤形

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1409551A (en) 1972-04-14 1975-10-08 Allen & Hanburys Ltd Cyclopent a indene derivatives
US4528290A (en) 1984-01-30 1985-07-09 Eli Lilly And Company Stimulating dopamine D-1 receptors
GB8606254D0 (en) 1986-03-13 1986-04-16 Wyeth John & Brother Ltd Substituted pyrimidoindoles
FR2664600B1 (fr) 1990-07-16 1994-09-02 Rhone Poulenc Sante Nouveau sel derive de la dialcoylaminoalcoyl-sulfonyl-26 pristinamycine iib.
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996008468A1 (en) * 1994-09-14 1996-03-21 H. Lundbeck A/S Carbamoyloxy amine compounds
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
JP2000044533A (ja) * 1998-03-26 2000-02-15 Santen Pharmaceut Co Ltd 新規ウレア誘導体
WO1999052525A1 (es) * 1998-04-15 1999-10-21 Laboratorios Del Dr. Esteve, S.A. Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos
WO1999065876A1 (en) * 1998-06-16 1999-12-23 R.J. Reynolds Tobacco Company Aryl substituted olefinic amines and their use as cholinergic receptors agonists
JP2005255694A (ja) * 2000-07-04 2005-09-22 Lts Lohmann Therapie-Systeme Ag 口腔または体腔内で有効成分を放出するための迅速分解性投与可能剤形
JP2004503589A (ja) * 2000-07-14 2004-02-05 ターガセプト，インコーポレイテッド Ｅ−メタニコチンのジアシル酒石酸塩を含有する組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511482A (ja) * 2002-10-02 2006-04-06 ターガセプト，インコーポレイテッド コリン作動性受容体を活性化できる化合物

Also Published As

Publication number Publication date
DE60108130D1 (de) 2005-02-03
ATE285773T1 (de) 2005-01-15
IL192287A0 (en) 2008-12-29
HUP0301553A3 (en) 2005-05-30
WO2002005798A2 (en) 2002-01-24
NO20030155D0 (no) 2003-01-13
CA2415901A1 (en) 2002-01-24
HUP0301553A2 (hu) 2003-08-28
EP1311265A2 (en) 2003-05-21
CN1468100A (zh) 2004-01-14
EP1311265B1 (en) 2004-12-29
AU2002222909B2 (en) 2005-12-15
NO20030155L (no) 2003-03-13
CN1680326A (zh) 2005-10-12
IL153577A0 (en) 2003-07-06
ZA200300135B (en) 2004-04-06
NZ523606A (en) 2004-12-24
IL153577A (en) 2009-07-20
DE60108130T2 (de) 2006-02-23
WO2002005798A3 (en) 2003-03-13
AU2290902A (en) 2002-01-30
US6432954B1 (en) 2002-08-13
BR0112130A (pt) 2003-09-02
PL360532A1 (en) 2004-09-06

Similar Documents

Publication Publication Date Title
US6492399B1 (en) Pharmaceutical compositions and methods for use
US6455554B1 (en) Oxopyridinyl pharmaceutical compositions and methods for use
KR100593433B1 (ko) 아릴 치환된 올레핀계 아민 및 콜린성 수용체 작용제로서의 그들의 용도
US20080249142A1 (en) Hydroxybenzoate salts of metanicotine compounds
US8778978B2 (en) Hydroxybenzoate salts of metanicotine compounds
WO2000075110A1 (en) Pharmaceutical compositions and methods for use
US6743812B1 (en) Pharmaceutical compositions and methods for use
US6432954B1 (en) Pharmaceutical compositions and methods for use
AU2002222909A1 (en) Pharmaceutical compositions for treating neurological disorders
US7060826B2 (en) Compounds capable of activating cholinergic receptors
AU2006202005B2 (en) Pharmaceutical compositions for treating neurological disorders
US20030087915A1 (en) Pharmaceutical compositions and methods for use
HK1082255A (en) Pharmaceutical compositions and methods for use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080708

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110607

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111108